1 February 2012 - Endologix Inc (NASDAQ:ELGX), a US-based developer of treatments for aortic disorders, said on Tuesday that it had enrolled the first patient in its US clinical trial to assess the Ventana Fenestrated Stent Graft System for the endovascular repair of juxtarenal and pararenal abdomin...

 

 

 

You must be logged in to view the whole article.
Click here if you require signing up